Candida bloodstream infections: Comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 561-566

  Pfaller, Michael A ^a   Moet, Gary J ^a   Messer, Shawn A ^a   Jones, Ronald N ^a,b   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COMMUNITY ONSET CANDIDEMIA; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; HOSPITAL ADMISSION; HOSPITAL INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SPECIES DISTRIBUTION;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDEMIA; CANDIDIASIS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; SPECIES SPECIFICITY; WORLD HEALTH;

EID: 78751679700     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01079-10     Document Type: Article

References (50)

1. Almirante, B., et al. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
2. Arnold, H. M., et al. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368.
3. Blumberg, H. M., et al. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33:177-186.
4. Castanheira, M., et al. 2010. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob. Agents Chemother. 54:2655-2659.
5. Chapeland-Leclerc, F., et al. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 54:1360-1362.
6. Chen, S., et al. 2006. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12:1508-1516.
7. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2008. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Corona, A., and M. Singer. 2009. Early-onset candidemia: an increasing problem? Crit. Care Med. 37:2652-2653.
10. Diekema, D. J., et al. 2003. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J. Clin. Microbiol. 41:3655-3660.
11. Diekema, D. J., et al. 2002. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. 40:1298-1302.
12. Dimopoulos, G., A. Velegraki, and M. E. Falagas. 2009. A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. Antimicrob. Agents Chemother. 53:1242-1244.
13. Eggimann, P., J. Garbino, and D. Pittet. 2003. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3:685-702.
14. Falagas, M. E., K. E. Apostolou, and V. D. Pappas. 2006. Attributable mortality of candidemia: a systematic review of matched cohort and casecontrol studies. Eur. J. Clin. Microbiol. Infect. Dis. 25:419-425.
15. Garey, K. W., et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
16. Garey, K. W., R. S. Turpin, D. T. Bearden, M. P. Pai, and K. J. Suda. 2007. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int. J. Antimicrob. Agents 29:557-562.
17. Hajjeh, R. A., et al. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
18. Johannes, R. S. 2008. Epidemiology of early-onset bloodstream infection and implications for treatment. Am. J. Infect. Control 36:S171.e13-17.
19. Kao, A. S., et al. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170.
20. Kollef, M. H., et al. 2008. Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI summit. Clin. Infect. Dis. 47(Suppl. 2):S55-S101.
21. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
22. Kung, H. C., et al. 2007. Community-onset candidemia at a university hospital, 1995-2005. J. Microbiol. Immunol. Infect. 40:355-363.
23. Labelle, A. J., S. T. Micek, N. Roubinian, and M. H. Kollef. 2008. Treatmentrelated risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 36:2967-2972.
24. Laupland, K. B., et al. 2007. Burden of community-onset bloodstream infection: a population-based assessment. Epidemiol. Infect. 135:1037-1042.
25. Leone, M., et al. 2003. Long-term epidemiological survey of Candida species: comparison of isolates found in an intensive care unit and in conventional wards. J. Hosp. Infect. 55:169-174.
26. Macphail, G. L., et al. 2002. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 45:141-145.
27. Méan, M., O. Marchetti, and T. Calandra. 2008. Bench-to-bedside review: Candida infections in the intensive care unit. Crit. Care. 12:204.
28. Messer, S. A., R. N. Jones, G. J. Moet, J. T. Kirby, and M. Castanheira. 2010. Anidulafungin potency compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp: results from the Global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 49:2984-2987.
29. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
30. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
31. Parkins, M. D., D. M. Sabuda, S. Elsayed, and K. B. Laupland. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618.
32. Pasqualotto, A. C., W. L. Nedel, T. S. Machado, and L. C. Severo. 2005. A comparative study of risk factors and outcome among outpatient-acquired and nosocomial candidaemia. J. Hosp. Infect. 60:129-134.
33. Pfaller, M. A., et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
34. Pfaller, M. A., et al. 2010. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 48:1592-1599.
35. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
36. Pfaller, M. A., and D. J. Diekema. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
37. Pfaller, M. A., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat., in press.
38. Pfaller, M. A., et al. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:3254-3259.
39. Pfaller, M. A., et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
40. Pfeiffer, C. D., et al. 2010. Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol. 48:2373-2380.
41. Playford, E. G., G. R. Nimmo, M. Tilse, and T. C. Sorrell. 2010. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J. Hosp. Infect. 76:46-51.
42. Shorr, A. F., et al. 2009. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit. Care Med. 37:2519-2526.
43. Shorr, A. F., et al. 2006. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit. Care Med. 34:2588-2595.
44. Slavin, M. A., et al. 2010. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J. Antimicrob. Chemother. 65:1042-1051.
45. Sofair, A. N., et al. 2006. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin. Infect. Dis. 43:32-39.
46. Sun, H. Y., and N. Singh. 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35:211-218.
47. Trick, W. E., S. K. Fridkin, J. R. Edwards, R. A. Hajjeh, and R. P. Gaynes. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35: 627-630.
48. Weinstein, M. P., et al. 1997. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin. Infect. Dis. 24:584-602.
49. Wisplinghoff, H., et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
50. Zilberberg, M. D., A. F. Shorr, and M. H. Kollef. 2008. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect. Control Hosp. Epidemiol. 29:978-980.